Today's Newshttp://www.pharmaceutical-business-review.com/en-us2009-07-02T13:19:11.195-04:002009-07-02T13:19:11.195-04:00Copyright 2009, Datamonitorhttp://regulatoryaffairs.pharmaceutical-business-review.com/news/bayer_files_patent_infringement_lawsuit_against_teva_020709Lawsuit concerns Teva's application for approval to market Levitra for the treatment of erectile dysfunction2009-07-02T13:19:11.195-04:00http://regulatoryaffairs.pharmaceutical-business-review.com/news/bayer_files_patent_infringement_lawsuit_against_teva_020709http://regulatoryaffairs.pharmaceutical-business-review.com/news/sanofi_aventis_receives_fda_approval_for_multaq_020709Multaq to treat patients with atrial fibrillation or atrial flutter2009-07-02T13:16:21.314-04:00http://regulatoryaffairs.pharmaceutical-business-review.com/news/sanofi_aventis_receives_fda_approval_for_multaq_020709http://specialitychemicals.pharmaceutical-business-review.com/news/dow_to_streamline_manufacturing_footprint_010709Calls for shutdown of a number of manufacturing assets, including ethylene and ethylene-derivative assets2009-07-02T04:16:37.95-04:00http://specialitychemicals.pharmaceutical-business-review.com/news/dow_to_streamline_manufacturing_footprint_010709http://www.pharmaceutical-business-review.com/news/myriad_genetics_spins_off_research_pharmaceutical_business_090702Myriad Genetics to claim approximately $400 million in tax deductions2009-07-02T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/myriad_genetics_spins_off_research_pharmaceutical_business_090702http://www.pharmaceutical-business-review.com/news/gsk_extends_product_portfolio_in_middle_east_north_africa_090702Business comprises a portfolio of 13 branded pharmaceuticals2009-07-02T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/gsk_extends_product_portfolio_in_middle_east_north_africa_090702http://www.pharmaceutical-business-review.com/news/biogen_idec_acorda_sign_collaboration_agreement_for_fampridinesr_090701Acorda to continue developing and commercializing Fampridine-SR in the US2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/biogen_idec_acorda_sign_collaboration_agreement_for_fampridinesr_090701http://www.pharmaceutical-business-review.com/news/graceway_signs_acquisition_license_agreement_with_pfizer_090701Graceway to acquire worldwide commercial rights for three investigational dermatological molecules from Pfizer2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/graceway_signs_acquisition_license_agreement_with_pfizer_090701http://www.pharmaceutical-business-review.com/news/morphotek_signs_collaboration_agreement_with_synageva_090701To develop therapeutic monoclonal antibodies for treatment of various forms of cancer and infectious disease2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/morphotek_signs_collaboration_agreement_with_synageva_090701http://www.pharmaceutical-business-review.com/news/sepracor_provides_update_on_clinical_trials_for_sep225289_lunesta_090701SEP-225289 did not meet the primary efficacy endpoint, but Lunesta has been proven to be safe and well tolerated2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/sepracor_provides_update_on_clinical_trials_for_sep225289_lunesta_090701http://www.pharmaceutical-business-review.com/news/shire_provides_results_for_phase_3b_vyvanse_study_090701Vyvanse improved the ability to focus and organize, as well as hyperactivity and impulsivity2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/shire_provides_results_for_phase_3b_vyvanse_study_090701http://www.pharmaceutical-business-review.com/news/scheringplough_presents_phase_ii_and_iii_data_for_corifollitropin_alfa_090701Corifollitropin Alfa provides treatment in Controlled Ovarian Stimulation for development of multiple follicles in women2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/scheringplough_presents_phase_ii_and_iii_data_for_corifollitropin_alfa_090701http://www.pharmaceutical-business-review.com/news/provectus_completes_patient_enrollment_in_phase_2_atopic_dermatitis_trial_090701PH-10, a topical drug for treatment of dermatologic diseases, including atopic dermatitis, a chronic skin condition2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/provectus_completes_patient_enrollment_in_phase_2_atopic_dermatitis_trial_090701http://regulatoryaffairs.pharmaceutical-business-review.com/news/combinatorx_signs_merger_agreement_with_neuromed_090701Merger to brings togather product assets and financial resources of both organizations2009-07-01T00:00:00.0+05:30http://regulatoryaffairs.pharmaceutical-business-review.com/news/combinatorx_signs_merger_agreement_with_neuromed_090701http://www.pharmaceutical-business-review.com/news/huhhot_xinheng_baide_acquires_raw_bovine_serum_collection_center_in_china_090701Acquisition to increase sales while reducing the raw material costs to reach maximum profits2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/huhhot_xinheng_baide_acquires_raw_bovine_serum_collection_center_in_china_090701http://www.pharmaceutical-business-review.com/news/teva_receives_fda_approval_for_oral_contraceptive_090701Tri-Lo Sprintec is a generic version of Ortho McNeil Janssen's oral contraceptive, Ortho Tri-Cyclen Lo2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/teva_receives_fda_approval_for_oral_contraceptive_090701http://www.pharmaceutical-business-review.com/news/inc_research_acquires_mds_pharma_services_phase_iiiv_operations_090701Divestiture is viewed as a result of MDS's ongoing strategic review process2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/inc_research_acquires_mds_pharma_services_phase_iiiv_operations_090701http://www.pharmaceutical-business-review.com/news/roche_launches_new_program_to_ease_tamiflu_access_090701Tamiflu Reserves Program designed as a pandemic insurance policy for the developing economies2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/roche_launches_new_program_to_ease_tamiflu_access_090701http://www.pharmaceutical-business-review.com/news/iressa_receives_marketing_authorisation_in_europe_090701For treatment of adults with locally advanced or metastatic non-small cell lung cancer, with activating mutations of EGFR-TK across all lines of therapy2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/iressa_receives_marketing_authorisation_in_europe_090701http://www.pharmaceutical-business-review.com/news/amags_feraheme_wins_fda_approval_090701As an iron replacement therapy for treatment of iron deficiency anemia in adult patients with chronic kidney disease2009-07-01T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/amags_feraheme_wins_fda_approval_090701http://www.pharmaceutical-business-review.com/news/spanish_government_novavax_sign_license_agreement_for_vaccine_technology_090630To use VLP technology to create comprehensive influenza vaccine solution for Spanish government, under a E60 million program2009-06-30T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/spanish_government_novavax_sign_license_agreement_for_vaccine_technology_090630http://www.pharmaceutical-business-review.com/news/cytrx_files_report_with_fda_in_response_to_partial_clinical_hold_on_arimoclomol_090630Arimoclomol, an orally administered molecular chaperone regulator drug candidate for treatment of ALS and stroke recovery2009-06-30T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/cytrx_files_report_with_fda_in_response_to_partial_clinical_hold_on_arimoclomol_090630http://www.pharmaceutical-business-review.com/news/wyeth_catalyst_sign_agreement_to_develop_commercialize_factor_viia_products_090630Wyeth to support the discovery, research and preclinical development2009-06-30T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/wyeth_catalyst_sign_agreement_to_develop_commercialize_factor_viia_products_090630http://www.pharmaceutical-business-review.com/news/vical_posts_100_response_in_preclinical_results_for_h1_influenza_vaccine_090630To start large- scale manufacturing of vaccine for human clinical trials2009-06-30T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/vical_posts_100_response_in_preclinical_results_for_h1_influenza_vaccine_090630http://www.pharmaceutical-business-review.com/news/efsa_issues_safety_statement_for_use_of_chromium_picolinate_090630Concluded that chromium picolinate does not present safety concern when used as source of chromium in food supplements2009-06-30T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/efsa_issues_safety_statement_for_use_of_chromium_picolinate_090630http://www.pharmaceutical-business-review.com/news/virginia_mason_to_implement_carefxs_fusionfx_solution_suite_090630Suite synchronizes patient data across existing systems, departments and facilities2009-06-30T00:00:00.0+05:30http://www.pharmaceutical-business-review.com/news/virginia_mason_to_implement_carefxs_fusionfx_solution_suite_090630